1.27. Analysis.

Comparison 1 BDP v BUD crossover design studies, no OCS: all doses, Outcome 27 Daytime use of rescue beta2 agonist (puffs/day).

Comparison 1 BDP v BUD crossover design studies, no OCS: all doses, Outcome 27 Daytime use of rescue beta2 agonist (puffs/day).